SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):October 6, 2004
IntraBiotics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 0-29993 | | 94-3200380 |
|
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
2483 East Bayshore Road, Suite 100
Palo Alto, California 94303
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:(650) 526-6800
Not Applicable
(Former name or former address, if changed since last report.)
TABLE OF CONTENTS
Item 8.01 Other Events.
On October 6, 2004, IntraBiotics Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it had retained Lazard to advise the Company in evaluating strategic options.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press release dated October 6, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | |
| | | | | INTRABIOTICS PHARMACEUTICALS, INC. |
| |
| Date: October 7, 2004 | | | | /s/ David Tucker
David Tucker
Principal Financial Officer |
EXHIBIT INDEX
| | | | | | | |
| Exhibit | | | | |
| Number | | Description | | | | |
| |
| | | | |
| 99.1 | | Press release dated October 6, 2004. |
